Clinical course of COVID-19 disease in immunosuppressed renal transplant patients
This work is licensed under a Creative Commons Attribution 4.0 International License..
Background/aim: We aimed to identify clinical settings of renal transplant patients with COVID-19.
Materials and methods: In this retrospective study, we included kidney transplant inpatients with laboratory confirmed COVID-19 who had been discharged or had died by October 1st, 2020. Characteristics of the patients, including basal and last outpatient biochemical parameters were recorded. Discontinuation or dosage reduction of immunosuppressives and other treatment information was documented.
Results: Twenty patients were included in this study, of whom 18 were discharged and 2 died in hospital. The mean duration of hospitalization and follow-up were 9.7 ± 6.4 days and 4.5 ± 2.0 months, respectively. Fourteen patients (70%) were male and mean age was 48.0 ± 10.3 years. At admission, all had immunosuppression withdrawn and were started on methylprednisolone 16 mg/ day (50%) or dexamethasone (50%). Tacrolimus/m-TOR inhibitors were reduced by 50% and all antimetabolites were discontinued. Hemodialysis was needed for 10% of patients. Acute kidney injury was detected in 25% of the patients. With respect to hospitalization time and complications, there was no significant difference between patients who used dexamethasone and those who did not (P > 0.05). The discontinued immunosuppressives were resumed within 2 to 4 weeks after discharge according to the severity of disease. No rehospitalization or acute rejection was detected during the follow-up of the patients.
Conclusion: Renal transplant patients are considered a high risk group for COVID-19. It can be said that discontinuation or reducing dosages of immunosuppressives may be effective and safe in kidney transplant patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:51 |
|---|---|
| Enthalten in: |
Turkish journal of medical sciences - 51(2021), 2 vom: 30. Apr., Seite 428-434 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dheir, Hamad [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 07.05.2021 Date Revised 25.06.2021 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3906/sag-2007-260 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM317528645 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM317528645 | ||
| 003 | DE-627 | ||
| 005 | 20231225163445.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3906/sag-2007-260 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1058.xml |
| 035 | |a (DE-627)NLM317528645 | ||
| 035 | |a (NLM)33185367 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dheir, Hamad |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical course of COVID-19 disease in immunosuppressed renal transplant patients |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.05.2021 | ||
| 500 | |a Date Revised 25.06.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a This work is licensed under a Creative Commons Attribution 4.0 International License. | ||
| 520 | |a Background/aim: We aimed to identify clinical settings of renal transplant patients with COVID-19 | ||
| 520 | |a Materials and methods: In this retrospective study, we included kidney transplant inpatients with laboratory confirmed COVID-19 who had been discharged or had died by October 1st, 2020. Characteristics of the patients, including basal and last outpatient biochemical parameters were recorded. Discontinuation or dosage reduction of immunosuppressives and other treatment information was documented | ||
| 520 | |a Results: Twenty patients were included in this study, of whom 18 were discharged and 2 died in hospital. The mean duration of hospitalization and follow-up were 9.7 ± 6.4 days and 4.5 ± 2.0 months, respectively. Fourteen patients (70%) were male and mean age was 48.0 ± 10.3 years. At admission, all had immunosuppression withdrawn and were started on methylprednisolone 16 mg/ day (50%) or dexamethasone (50%). Tacrolimus/m-TOR inhibitors were reduced by 50% and all antimetabolites were discontinued. Hemodialysis was needed for 10% of patients. Acute kidney injury was detected in 25% of the patients. With respect to hospitalization time and complications, there was no significant difference between patients who used dexamethasone and those who did not (P > 0.05). The discontinued immunosuppressives were resumed within 2 to 4 weeks after discharge according to the severity of disease. No rehospitalization or acute rejection was detected during the follow-up of the patients | ||
| 520 | |a Conclusion: Renal transplant patients are considered a high risk group for COVID-19. It can be said that discontinuation or reducing dosages of immunosuppressives may be effective and safe in kidney transplant patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a acute rejection | |
| 650 | 4 | |a immunosuppression | |
| 650 | 4 | |a kidney transplantation | |
| 650 | 4 | |a mortality | |
| 650 | 7 | |a Glucocorticoids |2 NLM | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 650 | 7 | |a Dexamethasone |2 NLM | |
| 650 | 7 | |a 7S5I7G3JQL |2 NLM | |
| 650 | 7 | |a Everolimus |2 NLM | |
| 650 | 7 | |a 9HW64Q8G6G |2 NLM | |
| 650 | 7 | |a Mycophenolic Acid |2 NLM | |
| 650 | 7 | |a HU9DX48N0T |2 NLM | |
| 650 | 7 | |a Tacrolimus |2 NLM | |
| 650 | 7 | |a WM0HAQ4WNM |2 NLM | |
| 650 | 7 | |a Methylprednisolone |2 NLM | |
| 650 | 7 | |a X4W7ZR7023 |2 NLM | |
| 700 | 1 | |a Sipahi, Savaş |e verfasserin |4 aut | |
| 700 | 1 | |a Yaylacı, Selçuk |e verfasserin |4 aut | |
| 700 | 1 | |a Çetin, Esma Seda |e verfasserin |4 aut | |
| 700 | 1 | |a Genç, Ahmed Bilal |e verfasserin |4 aut | |
| 700 | 1 | |a Fırat, Necattin |e verfasserin |4 aut | |
| 700 | 1 | |a Köroğlu, Mehmet |e verfasserin |4 aut | |
| 700 | 1 | |a Muratdağı, Gürkan |e verfasserin |4 aut | |
| 700 | 1 | |a Tomak, Yakup |e verfasserin |4 aut | |
| 700 | 1 | |a Özmen, Kezban |e verfasserin |4 aut | |
| 700 | 1 | |a Ateş, Ömer Faruk |e verfasserin |4 aut | |
| 700 | 1 | |a Karabay, Oğuz |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Turkish journal of medical sciences |d 1997 |g 51(2021), 2 vom: 30. Apr., Seite 428-434 |w (DE-627)NLM093849745 |x 1303-6165 |7 nnns |
| 773 | 1 | 8 | |g volume:51 |g year:2021 |g number:2 |g day:30 |g month:04 |g pages:428-434 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3906/sag-2007-260 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 51 |j 2021 |e 2 |b 30 |c 04 |h 428-434 | ||